## Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application.

1. (Currently amended) A compound of formula:

or the pharmaceutically acceptable salts or esters thereof, wherein

R<sup>1</sup> is selected from the group consisting of

Η,

lower alkyl that optionally may be substituted with a group selected from  $OR^6$ , cycloalkyl, and  $NR^7R^8$ ,

cycloalkyl,

COR<sup>9</sup>, and

 $SO_2R^{10}$ ;

R<sup>2</sup> is selected from the group consisting of

```
H,
F,
Cl, and
CH<sub>3</sub>;
```

R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> are each independently selected from the group consisting of H,

lower alkyl, which optionally may be substituted with a group selected from  $OR^6$  and  $NR^7R^8$ ,

```
OR<sup>11</sup>,
NR<sup>12</sup>R<sup>13</sup>,
halogen,
NO<sub>2</sub>,
CONR<sup>6</sup>R<sup>9</sup>,
NHSO<sub>2</sub>R<sup>14</sup>,
CN
S-lower alkyl,
OCF<sub>3</sub>, and
OCHF<sub>2</sub>,
```

or alternatively, R³ and R⁴ taken together with the two carbons and the bond between them from the benzene ring (D) to which R³ and R⁴ are attached can form a ring system having up to two additional rings, each of said rings having 5-7 atoms, and the ring attached to the benzene ring (D) optionally including one or more hetero atoms and being optionally substituted by lower alkyl,

provided that  $R^3$  and  $R^4$  or  $R^4$  and  $R^5$  are not simultaneously -OCH<sub>3</sub>, and provided further that  $R^4$  is not -CI when  $R^3$  or  $R^5$  is -NO<sub>2</sub>;

R<sup>6</sup> and R<sup>9</sup> are independently selected from the group consisting of H, and lower alkyl that optionally may be substituted by OH and halogen;

R<sup>7</sup> and R<sup>8</sup> are independently selected from the group consisting of
 H, and
 lower alkyl that optionally may be substituted by OR<sup>6</sup>,

or, alternatively, R<sup>7</sup> is H and R<sup>8</sup> is OH,

or, alternatively, NR<sup>7</sup>R<sup>8</sup> can optionally form a ring having 5-6 <u>ring</u> atoms, said ring <u>atoms comprising</u>, in addition to the nitrogen atom to which R<sup>7</sup> and R<sup>8</sup> are bonded, <u>carbon ring atoms</u>, said carbon ring atoms optionally <u>being replaced by including</u> one or more additional hetero atoms and <u>said ring atoms</u> being optionally substituted by the group consisting of one or more of OR<sup>6</sup> and lower alkyl which itself may be optionally substituted by OH;

R<sup>10</sup> is selected from the group consisting of lower alkyl which optionally may be substituted by one or more chlorine or fluorine, and

 $NH_2$ ;

R<sup>11</sup> is selected from the group consisting of

H, and

lower alkyl that optionally may be substituted by OR<sup>6</sup>, COOH, halogen and NR<sup>15</sup>R<sup>16</sup>;

 ${\sf R}^{\sf 12}$  and  ${\sf R}^{\sf 13}$  are independently selected from the group consisting of H,

lower alkyl that optionally may be substituted with a group selected from OR<sup>6</sup>, COOH and NR<sup>15</sup>R<sup>16</sup>.

COR<sup>17</sup>, and SO<sub>2</sub>R<sup>18</sup>.

provided that only one of R<sup>12</sup> and R<sup>13</sup> is COR<sup>17</sup> or SO<sub>2</sub>R<sup>18</sup>,

or alternatively NR<sup>12</sup>R<sup>13</sup> can optionally form a ring having 5-6 <u>ring</u> atoms, said ring <u>atoms comprising</u>, in addition to the nitrogen atom to which R<sup>12</sup> and R<sup>13</sup> are <u>bonded</u>, carbon ring atoms, said carbon ring atoms optionally <u>being replaced by including</u> one or more additional hetero atoms and <u>said ring atoms</u> being optionally substituted by the group consisting of one or more of OR<sup>6</sup> and lower alkyl which itself may be optionally substituted by OH;

R<sup>14</sup> is lower alkyl;

R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of H, and

lower alkyl that optionally may be substituted by OH,

or alternatively NR<sup>15</sup>R<sup>16</sup> can optionally form a ring having 5-6 <u>ring</u> atoms, said ring <u>atoms comprising</u>, in <u>addition to the nitrogen atom to which R<sup>15</sup> and R<sup>16</sup> are bonded, carbon ring atoms, said carbon ring atoms optionally being replaced by including one or more additional hetero atoms and <u>said ring atoms</u> being optionally substituted by the group consisting of one or more of OR<sup>6</sup> and lower alkyl which itself may be optionally substituted by OH;</u>

R<sup>17</sup> is selected from the group consisting of

H, and

lower alkyl which optionally may be substituted with a group selected from OH, COOH and  ${\rm NR}^{15}{\rm R}^{16}$ ; and

R<sup>18</sup> is lower alkyl.

- 2. (Original) The compound of claim 1 wherein R<sup>1</sup> is selected from the group consisting of H, CH<sub>2</sub>CH<sub>2</sub>OH, CH<sub>2</sub>CH<sub>2</sub>OH, CH3CO-, CH(CH<sub>3</sub>)<sub>2</sub>, CH<sub>2</sub>CH(CH<sub>3</sub>)<sub>2</sub>, cyclopropylmethyl and CH<sub>3</sub>.
- 3. (Original) The compound of claim 2 wherein R<sup>1</sup> is selected from the group consisting of H, methyl, CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH and CH(CH<sub>3</sub>)<sub>2</sub>.
- 4. (Original) The compound of claim 1 wherein R<sup>2</sup> is selected from the group consisting of H and fluorine.
  - 5. (Original) The compound of claim 4 wherein R<sup>2</sup> is H.

- 6. (Original) The compound of claim 2 wherein R<sup>2</sup> is selected from the group consisting of H and fluorine.
  - 7. (Original) The compound of claim 3 wherein  $R^2$  is H.
- 8. (Original) The compound of claim 1 wherein R<sup>3</sup> is selected from the group consisting of OR<sup>11</sup>, lower alkyl, NH2, Cl, F, H, OCHF<sub>2</sub> and NO<sub>2</sub>.
- 9. (Original) The compound claim 6 wherein R<sup>3</sup> is selected from the group consisting of OR<sup>11</sup>, lower alkyl, NH2, Cl, F, H, OCHF<sub>2</sub> and NO<sub>2</sub>.
- 10. (Original) The compound of claim 7 wherein R<sup>3</sup> is selected from the group consisting of F, OCH<sub>3</sub> and CH<sub>2</sub>CH<sub>3</sub>.
- 11. (Original) The compound of claim 8 wherein R<sup>3</sup> is selected from the group consisting of F, OCH<sub>3</sub> and CH<sub>2</sub>CH<sub>3</sub>.
- 12. (Original) The compound of claim 1 wherein R<sup>4</sup> is selected from the group consisting of acetamido, chloro, diethylamino, hydrogen, hydroxy, hydroxy-ethylamino, [1-(hydroxymethyl)-3-methylbutyl]amino, 1-(3-hydroxymethyl) piperidinyl, 4-hydroxy-1-piperidinyl, methoxy, 2-methoxyethylamino, 2-methyl-1-pyrrolidinyl, morpholino, piperidinyl, pyrrolidinyl.
- 13. (Original) The compound of claim 12 wherein R<sup>4</sup> is selected from the group consisting of H and CH<sub>3</sub>O-.

ξ,

- 14. (Original) The compound of claim 9 wherein R<sup>4</sup> is selected from the group consisting of acetamido, chloro, diethylamino, hydrogen, hydroxy, hydroxy-ethylamino, [1-(hydroxymethyl)-3-methylbutyl]amino, 1-(3-hydroxymethyl) piperidinyl, 4-hydroxy-1-piperidinyl, methoxy, 2-methoxyethylamino, 2-methyl-1-pyrrolidinyl, morpholino, piperidinyl and pyrrolidinyl.
- 15. (Original) The compound of claim 10, wherein R<sup>4</sup> is selected from the group consisting of acetamido, chloro, diethylamino, hydrogen, hydroxy, hydroxy-ethylamino, [1-(hydroxymethyl)-3-methylbutyl]amino, 1-(3-hydroxymethyl) piperidinyl, 4-hydroxy-1-piperidinyl, methoxy, 2-methoxyethylamino, 2-methyl-1-pyrrolidinyl, morpholino, piperidinyl and pyrrolidinyl.
- 16. (Previously presented) The compound of claim 11, wherein R<sup>4</sup> is selected from the group consisting of acetamido, chloro, diethylamino, hydrogen, hydroxy, hydroxy-ethylamino, [1-(hydroxymethyl)-3-methylbutyl]amino, 1-(3-hydroxymethyl) piperidinyl, 4-hydroxy-1-piperidinyl, methoxy, 2-methoxyethylamino, 2-methyl-1-pyrrolidinyl, morpholino, piperidinyl and pyrrolidinyl.

17 - 24. (Cancelled)

- 25. (Original) The compound of claim 1 wherein  $R^5$  is selected from the group consisting of H and F.
  - 26. (Original) The compound of claim 25 wherein R<sup>5</sup> is F.

27 - 28. (Cancelled)

29. (Currently amended) The A compound of claim 26 which is selected from the group consisting of:

[4-Amino-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (3,5-difluorophenyl)methanone,

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,5-difluoro-phenyl)-methanone,

(4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3,5-difluoro-phenyl)-methanone,

{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,5-difluoro-phenyl)-methanone, and

[4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3,4,5-trifluorophenyl)-methanone.

- 30. (Original) The compound of claim 25 wherein R<sup>5</sup> is H.
- 31. (Original) The compound of claim 1 wherein at least one of  $R^3$ ,  $R^4$  and  $R^5$  is halogen.
- 32. (Currently amended) The A compound of claim 31 which is selected from the group consisting of:

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3,4-dichlorophenyl)methanone,

[4-Amino-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (3-fluorophenyl)methanone,

[4-Amino-2-[[4-(1-piperazinyl)phenyl]amino]-5-thiazolyl](3-fluorophenyl) methanone,

(4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-fluoro-phenyl)-methanone,

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluorophenyl)-methanone,

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,4,5-trifluoro-phenyl)-methanone,

(4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3,4-difluoro-phenyl)-methanone,

(4-Amino-2-{4-[4-(2-hydroxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-fluoro-phenyl)-methanone,

{4-Amino-2-[4-(4-sec-butyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluoro-phenyl)-methanone,

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluorophenyl)-methanone, and

{4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluoro-phenyl)-methanone.

- 33. (Original) The compound of claim 1 wherein at least one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is selected from the group consisting of OR<sup>11</sup>, OCF<sub>3</sub>, and OCHF<sub>2</sub>.
- 34. (Currently amended) The <u>A</u> compound of claim 33 which is selected from the group consisting of:

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl]-(4-hydroxyphenyl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](4-methoxyphenyl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3-fluoro-4-methoxyphenyl)methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3-methoxyphenyl)methanone,

- [4-Amino-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3,5-dimethoxyphenyl)methanone,
- [4-Amino-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3-methoxyphenyl)methanone,
- [4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl](3-methoxyphenyl)methanone,
- [4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (3,5-dimethoxyphenyl)methanone,
- [4-Amino-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (3-methoxyphenyl)methanone, and
- [4-Amino-2-[[4-(1-piperazinyl)phenyl]amino)-5-thiazolyl](3-fluoro-4-methoxyphenyl)methanone.
- 35. (Currently amendedl) The  $\underline{A}$  compound of claim 33 which is selected from the group consisting of:
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-methoxy-phenyl)-methanone,

- (4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-methoxy-phenyl)-methanone,
- 4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-fluoro-4-methoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(4-fluoro-3-methoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluoro-4-methoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(4-difluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-trifluoromethoxy-phenyl)-methanone,
- (4-Amino-2-{4-[4-(2-methoxy-ethyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-methoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3,5-difluoro-4-methoxy-phenyl)-methanone, and
- {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(4-fluoro-3-methoxy-phenyl)-methanone.

- 36. (Currently amended) The  $\underline{A}$  compound of claim 33 which is selected from the group consisting of:
- {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-trifluoromethoxy-phenyl)-methanone,
- [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3,5-difluoro-4-methoxy-phenyl)-methanone,
- [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(4-fluoro-3-methoxy-phenyl)-methanone,
- [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3-trifluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-trifluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-difluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-hydroxy-phenyl)-methanone,

- {4-Amino-2-[4-(4-isobutyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-hydroxy-phenyl)-methanone,
- [4-Amino-2-(4-piperazin-1-yl-phenylamino)-thiazol-5-yl]-(3-difluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-difluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-methoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluoro-4-hydroxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-difluoromethoxy-phenyl)-methanone,
- {4-Amino-2-[4-(4-cyclopropylmethyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-fluoro-4-methoxy-phenyl)-methanone, and
- {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-hydroxy-phenyl)-methanone.
- 37. (Previously presented) The compound of claim 1 wherein each of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is independently selected from H, NO<sub>2</sub>, NHSO<sub>2</sub>R<sup>4</sup> and NR<sup>12</sup>R<sup>13</sup>.

- 38. (Currently amended) The  $\underline{A}$  compound of claim 37 which is selected from the group consisting of:
- [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][4-(1-pyrrolidinyl)phenyl]methanone,
- [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][4-(1-piperidinyl)phenyl]methanone,
- [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][4-(4-morpholinyl)phenyl]methanone, acetate salt,
- [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl](3-nitrophenyl)methanone,
- [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][4-(diethylamino)phenyl]methanone,
- N-[4-[[4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl]carbonyl]phenyl]acetamide,
- [4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] [4-(diethylamino)phenyl]methanone,

1-Acetyl-4-[4-[[4-amino-5-[4-(diethylamino)benzoyl]-2-thiazolyl]amino] phenyl]piperazine, trifluoroacetate salt,

[4-Amino-2-[[4-[4-(2-hydroxyethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] [4-(1-pyrrolidinyl)phenyl]methanone,

[4-Amino-2-[[4-(1-piperazinyl)phenyl]amino)-5-thiazolyl][4-(1-pyrrolidinyl) phenyl]methanone, and

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][4-(2-hydroxyethyl)amino-3-nitrophenyl]methanone.

39. (Currently amendedl) The <u>A</u> compound of claim 37 which is selected from the group consisting of:

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-nitro-4-(1-pyrrolidinyl)phenyl]methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-nitro-4-(4-morpholinyl)phenyl]methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-nitro-4-[(2-methoxyethyl)amino]phenyl]methanone,

racemic [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl] [3-nitro-4-[3-(hydroxymethyl)-1-piperidinyl]phenyl]methanone,

racemic [4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl] [3-nitro-4-(2-methyl-1-pyrrolidinyl)phenyl]methanone,

(R)-[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-nitro-4-[[1-(hydroxymethyl)-3-methylbutyl]amino]phenyl]methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-nitro-4-(4-hydroxy-1-piperidinyl)phenyl]methanone,

[4-Amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl][3-amino-4-(4-pyrrolidinyl)phenyl]methanone, and

- (R)-[3-Amino-4-[[1-(hydroxymethyl)-3-methylbutyl]amino]phenyl][4-amino-2-[[4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl]methanone.
- 40. (Currently amendedl) The  $\underline{A}$  compound of claim 37 which is selected from the group consisting of:

[4-Amino-2-[[3-fluoro-4-(4-methyl-1-piperazinyl)phenyl]amino]-5-thiazolyl] [4-(1-pyrrolidinyl)phenyl]methanone,

(4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-nitro-phenyl)-methanone,

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(4-piperidin-1-yl-phenyl)-methanone, and

{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(4-morpholin-4-yl-phenyl)-methanone.

- 41. (Original) The compound of claim 1 wherein any one or more of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is CN.
- 42. (Currently amended) The A compound of claim 41 which is selected from the group consisting of:
- 3-(4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazole-5-carbonyl)-benzonitrile,
- 3-{4-Amino-2-[4-(4-isopropyl-piperazin-1-yl)-phenylamino]-thiazole-5-carbonyl}-benzonitrile, and
- 3-{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazole-5-carbonyl}-benzonitrile.
- 43. (Original) The compound of claim 1 wherein each one of  $R^3$ ,  $R^4$  and  $R^5$  is independently selected from H and lower alkyl.
- 44. (Currently amended) The A compound of claim 43 which is selected from the group consisting of:

(4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-m-tolyl-methanone,

(4-Amino-2-{4-[4-(3-hydroxy-propyl)-piperazin-1-yl]-phenylamino}-thiazol-5-yl)-(3-ethyl-phenyl)-methanone,

{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-(3-ethyl-phenyl)-methanone, and

{4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}-m-tolyl-methanone.

- 45. (Previously presented) The compound of claim 1 wherein at least one of R<sup>3</sup>, R<sup>4</sup> and R<sup>5</sup> is selected from S-lower alkyl.
- 46. (Currently amended) The compound of claim 45 which is {4-Amino-2-[4-(4-methyl-piperazin-1-yl)-phenylamino]-thiazol-5-yl}(3\_methylsulfanyl-phenyl)-methanone.
  - 47. (Previously presented) The compound

[4-Amino-2-[[4-[4-(1-methylethyl)-1-piperazinyl]phenyl]amino]-5-thiazolyl] (3-methoxyphenyl)methanone.

48 – 52. (Canceled)

## 53. (Currently amended) A compound of formula:

or the pharmaceutically acceptable salts or esters thereof, wherein

R<sup>1</sup> is selected from the group consisting of

H, and

lower alkyl that optionally may be substituted by OR<sup>6</sup>;

R<sup>2</sup> is selected from the group consisting of H and F;

R<sup>3</sup> is selected from the group consisting of

Η,

lower alkyl

halogen,

NR<sup>12</sup>R<sup>13</sup>,

NO<sub>2</sub>,

OCHF<sub>2</sub>, and

OR<sup>11</sup>;

```
R^4 is selected from the group consisting of H, lower alkyl that optionally may be may be substituted by OR^6, halogen, NR^{12}R^{13}.
```

or alternatively, R³-and R⁴-taken together with the two carbons and the bond between them from the benzene ring (D) to which R³-and R⁴- are attached can form a ring system having up to two additional rings, each of said rings having 5-7 atoms, and the ring attached to the benzene ring (D) optionally including one or more hetero atoms and being optionally substituted by lower alkyl,

```
provided that R<sup>4</sup> is not -CI when R<sup>3</sup> is -NO<sub>2</sub>;

R<sup>5</sup> is selected from the group consisting of H,
OR<sup>11</sup>, and
F;

R<sup>6</sup> is selected from the group consisting of H, and methyl;

R<sup>11</sup> is selected from the group consisting of H, and
```

lower alkyl that optionally may be substituted by a group selected from OR<sup>6</sup>, COOH, halogen and NR<sup>15</sup>R<sup>16</sup>;

R<sup>12</sup> and R<sup>13</sup> are independently selected from the group consisting of H,

lower alkyl that optionally may be substituted with a group selected from  ${\rm OR}^6$ , COOH and  ${\rm NR}^{15}{\rm R}^{16}$ ,

or alternatively NR<sup>12</sup>R<sup>13</sup> can optionally form a ring having 5-6 <u>ring</u> atoms, said ring <u>atoms comprising</u>, in <u>addition to the nitrogen atom to which R<sup>12</sup> and R<sup>13</sup> are bonded, carbon ring atoms, said carbon ring atoms optionally being replaced by including one or more additional hetero atoms and <u>said ring atoms</u> being optionally substituted by the group consisting of one or more of OR<sup>6</sup> and lower alkyl which itself may be optionally substituted by OH; and</u>

R<sup>15</sup> and R<sup>16</sup> are independently selected from the group consisting of H, and lower alkyl that optionally may be substituted by OH,

or alternatively NR<sup>15</sup>R<sup>16</sup> can optionally form a ring having 5-6 <u>ring</u> atoms, said ring <u>atoms comprising</u>, in addition to the nitrogen atom to which R<sup>15</sup> and R<sup>16</sup> are <u>bonded</u>, carbon ring atoms, said carbon ring atoms optionally <u>being replaced by including</u> one or more additional hetero atoms and <u>said ring atoms</u> being optionally substituted by the group consisting of one or more of OR<sup>6</sup> and lower alkyl which itself may be optionally substituted by OH.

## 54. (Original) A compound of formula:

or the pharmaceutically acceptable salts or esters thereof, wherein

R<sup>1</sup> is selected from the group consisting of

Η,

CH<sub>2</sub>CH<sub>2</sub>OH,

CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH,

CH<sub>3</sub>CO-, .

 $CH(CH_3)_2$ ,

 $CH_2CH(CH_3)_2$ ,

cyclopropylmethyl, and

CH<sub>3</sub>;

R<sup>2</sup> is selected from the group consisting of H and F;

 $R^3$  is selected from the group consisting of  $OR^{11}$ ,

lower alkyl,

NH<sub>2</sub>,

CI,

F,

Η,

OCHF<sub>2</sub>, and

NO<sub>2</sub>;

R<sup>4</sup> is selected from the group consisting of

H, and

diethylamino;

R<sup>5</sup> is H; and

R<sup>11</sup> is unsubstituted lower alkyl.

55. (Original) A compound of formula:

or the pharmaceutically acceptable salts or esters thereof, wherein

R<sup>1</sup> is selected from the group consisting of H,
CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>OH,
CH(CH<sub>3</sub>)<sub>2</sub>,
CH<sub>3</sub>, and
cyclopropylmethyl;

R<sup>2</sup>, R<sup>4</sup> and R<sup>5</sup> are H; and

 $R^3$  is selected from the group consisting of  $OCH_3$ , F, and  $CH_2CH_3$ .

- 56. (Original) A pharmaceutical composition comprising as an active ingredient an effective amount of a compound of claim 1 and a pharmaceutically acceptable carrier or excipient.
- 57. (Original) The pharmaceutical composition of claim 56 which is suitable for parenteral administration.

58 - 59. (Canceled)

60. (Previously presented) A method of treating breast, colon, lung or prostate cancer comprising administering to a subject in need of such therapy a therapeutically effective amount of a compound according to claim 1.

61 – 65. (Canceled)